Anti-FOLR2 antibody

Anti-FOLR2 antibody

• DataSheet
• Material Safety Data Sheets (MSDS)

Rabbit monoclonal to FOLR2

WB, IHC-P

Human FOLR2

FBP antibody; Fbp2 antibody; FR-P3 antibody; FR-BETA antibody; BETA-HFR antibody; FBP/PL-1 antibody; FR-P3 antibody; Folbp2 antibody; FR-beta antibody; Folbp-2 antibody; BETA-HFR antibody; FBP/PL-1 antibody; FBP2 antibody; Folbp2 antibody; Folbp-2 antibody; FOLR2 antibody; Folr2 antibody; FR-BETA antibody; FR-P3 antibody; FR-P3 antibody

Rabbit IgG

This antibody was obtained from a rabbit immunized with purified, recombinant Human FOLR2 (rh FOLR2; P14207-1; Met1-His228).

Monoclonal

0.2 μm filtered solution in PBS with 5% trehalose

This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.

Folate receptor beta, also known as Folate receptor 2, FBP, and FOLR2, is a member of the folate receptor family. FOLR2 is expressed in placenta and hematopoietic cells. The expression of FOLR2 is increased in malignant tissues. Members of the Folate receptor family members (FOLRs) have a high affinity for folic acid and for several reduced folic acid derivatives. They mediate the delivery of 5-methyltetrahydrofolate to the interior of, out of within, or between cells in a process known as potocytosis. FOLR2 has a 68% and 79% sequence homology with the FOLR1 and FOLR3 proteins, respectively. The FOLR2 protein was originally thought to exist only in placenta, but is also detected in spleen, bone marrow, and thymus. FOLR2 is a marker for macrophages generated in the presence of M-CSF, but not GM-CSF. Its expression correlates with increased folate uptake ability. Folate conjugates of therapeutic drugs are a potential immunotherapy tool to target tumor-associated macrophages.

• van Heyningen V, et al., 1995, Cytogenet Cell Genet. 69 (3-4): 127-58.
• Sabharanjak, S. et al., 2004, Adv Drug Deliv Rev. 56 (8): 1099-109. 
• Scapoli, L. et al., 2005, Am J Med Genet A. 132A (3): 302-4.
• Puig-Kröger, A. et al., 2009, Cancer Res  69 (24): 9395-403.